Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma Retraction in /10.3892/or.2023.8595

Zhao,Cui‑Cui; Chen,Jing; Niu,Rui‑Fang; Liu,Yan; Zhang,Chuan‑Gui

doi:10.3892/or.2018.6736

Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma

Retraction in: /10.3892/or.2023.8595

Authors:
- Cui‑Cui Zhao
- Jing Chen
- Rui‑Fang Niu
- Yan Liu
- Chuan‑Gui Zhang
View Affiliations

Affiliations: Department of VIP Ward, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of VIP Ward, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
Published online on: September 26, 2018 https://doi.org/10.3892/or.2018.6736
Pages: 3392-3404
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistin is considered to be a risk factor for several types of cancer, but its functions are controversial and not well studied in lung cancer. The present study is aimed to investigate the expression of resistin in lung adenocarcinoma tissues, in order to evaluate its association with the clinicopathological characteristics of cancer patients and to investigate the effects of resistin in lung adenocarcinoma cells. A total of 70 pairs of lung adenocarcinoma tissues and normal tissues were collected and immunohistochemistry was performed to examine resistin expression. Resistin overexpressed cells were established by plasmid transfection in A549 or H1975 cells. Alterations in cell proliferation, apoptosis, migration and invasion were analyzed in vitro. A nude mouse tumorigenicity assay was used to test the effect of resistin in vivo. High expression of resistin was predominantly observed in lung adenocarcinoma tissues but not in adjacent normal lung tissues. Resistin expression was significantly associated with increased tumor size, clinical stage as well as lymph node metastasis while negatively associated with progression-free survival (PFS) and overall survival (OS). Expression of resistin was an independent risk factor for PFS and OS. Overexpression of resistin promoted significant proliferation, migration and invasion, while also inhibited apoptosis in vitro. Resistin also promoted tumor formation in nude mice. The potential molecular mechanism was also investigated by in vitro experiments. In conclusion, the present study revealed that a high level of resistin expression in lung adenocarcinoma tissues is associated with poor clinicopathological status and survival. Resistin, which promotes the development of lung adenocarcinoma in vitro and in vivo may be a novel target for lung adenocarcinoma.

View Figures

View References

1	Slomian G, Świętochowska E, Malinowska-Borowska J, Kasperczyk S, Rogalska A and Nowak P: Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep. 66:902–907. 2014. View Article : Google Scholar : PubMed/NCBI
2	Sălăgeanu A, Tucureanu C, Lerescu L, Caraş I, Pitica R, Gangurà G, Costea R and Neagu S: Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life. 3:416–420. 2010.PubMed/NCBI
3	Zemanová M, Staňková B, Ušiakova Z, Tvrzická E, Pazdro A, Petruželka L and Zeman M: Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: A pilot study. Med Sci Monit. 20:2351–2357. 2014. View Article : Google Scholar : PubMed/NCBI
4	Dalamaga M: Resistin as a biomarker linking obesity and inflammation to cancer: Potential clinical perspectives. Biomark Med. 8:107–118. 2014. View Article : Google Scholar : PubMed/NCBI
5	Jiang CY, Wang W, Yin YL, Yuan ZR and Wang LB: Expression of the adipocytokine resistin and its association with the clinicopathological features and prognosis of pancreatic ductal adenocarcinoma. Oncol Lett. 4:960–964. 2012. View Article : Google Scholar : PubMed/NCBI
6	Nakajima TE, Yamada Y, Hamano T, Furuta K, Oda I, Kato H, Kato K, Hamaguchi T and Shimada Y: Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol. 136:261–266. 2010. View Article : Google Scholar : PubMed/NCBI
7	Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T and Shimada Y: Adipocytokine levels in gastric cancer patients: Resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 44:685–690. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gonullu G, Kahraman H, Bedir A, Bektas A and Yücel I: Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. 25:205–212. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sun CA, Wu MH, Chu CH, Chou YC, Hsu GC, Yang T, Chou WY, Yu CP and Yu JC: Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat. 123:869–876. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kang JH, Yu BY and Youn DS: Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 22:117–121. 2007. View Article : Google Scholar : PubMed/NCBI
11	Hlavna M, Kohut L, Lipkova J, Bienertova-Vasku J, Dostalova Z, Chovanec J and Vasku A: Relationship of resistin levels with endometrial cancer risk. Neoplasma. 58:124–128. 2011. View Article : Google Scholar : PubMed/NCBI
12	Filková M, Haluzík M, Gay S and Senolt L: The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 133:157–170. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lee YC, Chen YJ, Wu CC, Lo S, Hou MF and Yuan SS: Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol Oncol. 125:742–750. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES, Kim MK, Kim W and Myung SC: Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int. 108:E77–E83. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ntikoudi E, Kiagia M, Boura P and Syrigos KN: Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev. 40:22–30. 2014. View Article : Google Scholar : PubMed/NCBI
16	Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I and Syrigos KN: The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 61:391–397. 2008. View Article : Google Scholar : PubMed/NCBI
17	Kuo CH, Chen KF, Chou SH, Huang YF, Wu CY, Cheng DE, Chen YW, Yang CJ, Hung JY and Huang MS: Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway. Carcinogenesis. 34:2600–2609. 2013. View Article : Google Scholar : PubMed/NCBI
18	Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M and Garcia JM: Adipokines in patients with cancer anorexia and cachexia. J Investig Med. 58:554–559. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kim HS, Kim KJ, Kim B, Choi HC, Kwon JH and Choi DR: Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 71:1591–1597. 2013. View Article : Google Scholar : PubMed/NCBI
20	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
21	Tsai CH, Tsai HC, Huang HN, Hung CH, Hsu CJ, Fong YC, Hsu HC, Huang YL and Tang CH: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells. Oncotarget. 6:258–270. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wågsater D, Mumtaz M, Lofgren S, Hugander A and Dimberg J: Resistin in human colorectal cancer: Increased expression independently of resistin promoter −420C > G genotype. Cancer Invest. 26:1008–1014. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC, Tsai CH, Chiu WC, Chu-Sung Hu S, Lu CW, et al: Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 37:589–600. 2018. View Article : Google Scholar : PubMed/NCBI
24	Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T and Shimada Y: Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 101:1286–1291. 2010. View Article : Google Scholar : PubMed/NCBI
25	Diakowska D, Markocka-Mączka K, Szelachowski P and Grabowski K: Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. Dis Markers. 2014:6196492014. View Article : Google Scholar : PubMed/NCBI
26	Zheng L, Weng M, He J, Yang X, Jiang G and Tong Q: Expression of resistin-like molecule beta in gastric cancer: Its relationship with clinicopathological parameters and prognosis. Virchows Arch. 456:53–63. 2010. View Article : Google Scholar : PubMed/NCBI
27	Joshi RK, Kim WJ and Lee SA: Association between obesity-related adipokines and colorectal cancer: A case-control study and meta-analysis. World J Gastroenterol. 20:7941–7949. 2014. View Article : Google Scholar : PubMed/NCBI
28	Neilson AP, Djuric Z, Land S and Kato I: Plasma levels of resistin-like molecule beta in humans. Cancer Epidemiol. 35:485–489. 2011. View Article : Google Scholar : PubMed/NCBI
29	Gasiorowska A, Talar-Wojnarowska R, Kaczka A, Borkowska A, Czupryniak L and Małecka-Panas E: Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer. Pancreatology. 13:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
30	Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, Wassertheil-Smoller S, Xue X, Rajpathak SN, Chlebowski RT, et al: Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res. 72:3029–3037. 2012. View Article : Google Scholar : PubMed/NCBI
31	Grivennikov SI and Karin M: Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 70 Suppl 1:i104–i108. 2011. View Article : Google Scholar : PubMed/NCBI
32	Gong WJ, Liu JY, Yin JY, Cui JJ, Xiao D, Zhuo W, Luo C, Liu RJ, Li X, Zhang W, et al: Resistin facilitates metastasis of lung adenocarcinoma via TLR4/Src/EGFR/PI3K/NF-κB pathway. Cancer Sci. 109:2391–2400. 2018. View Article : Google Scholar : PubMed/NCBI